Table 3. MTX- and 7-OH-MTX plasma concentrations at 24 and 48 h in patients also taking benzimidazoles or who had been treated with NSAIDS prior to MTX.
| Geom. mean (95% CI) (µmol L−1) | |||||
|---|---|---|---|---|---|
| 24-h plasma conc. | 48-h plasma conc | ||||
| Patient subgroup | n | MTX | 7-OH-MTX | MTX | 7-OH-MTX |
| +Benzimidazoles | 13 | 2.01 (1.44–2.81) | 4.47 (3.17–6.31) | 0.25 (0.17–0.35) | 1.11 (0.73–1.68) |
| No benzimidazoles | 63 | 0.66 (0.52–0.84) | 2.52 (1.99–3.20) | 0.12 (0.09–0.15) | 0.72 (0.53–0.98) |
| Ratio | 3.03 (2.19–4.19) | 1.77 (1.27–2.48) | 2.10 (1.50–2.95) | 1.53 (1.04–2.26) | |
| P-value | <10−4 | 0.0009 | <10−4 | 0.031 | |
| Prior NSAIDs | 6 | 0.98 (0.63–1.51) | 1.74 (1.10–2.76) | 0.17 (0.11–0.28) | 1.61 (0.93–2.80) |
| No NSAIDs | 70 | 0.77 (0.62–0.97) | 2.83 (2.25–3.55) | 0.13 (0.10–0.16) | 0.73 (0.55–0.99) |
| Ratio | 1.26 (0.84–1.91) | 0.61 (0.40–0.95) | 1.34 (0.84–2.13) | 2.20 (1.33–3.65) | |
| P-value | 0.26 | 0.27 | 0.21 | 0.0023 | |